05.06.2013 Views

Download (PDF, 6.71MB) - TEEB

Download (PDF, 6.71MB) - TEEB

Download (PDF, 6.71MB) - TEEB

SHOW MORE
SHOW LESS

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

5.3<br />

REWARDING BENEFITS THROUGH PAYMENTS AND MARKETS<br />

THE ECONOMICS OF ACCESS AND<br />

BENEFIT SHARING (ABS)<br />

“My father said: You must never try<br />

to make all the money that's in a deal.<br />

Let the other fellow make some money<br />

too, because if you have a reputation<br />

for always making all the money, you<br />

won't have many deals.”<br />

J. Paul Getty<br />

This section looks at economic factors that influence<br />

the value of genetic resources (5.3.1) and considers<br />

ways to overcome current constraints on maximising<br />

such value (5.3.2). This is a key issue to those who<br />

own genetic resources or involved in land use decisions<br />

that affect them. Typically such groups are<br />

made up of relatively poor rural farming or indigenous<br />

communities. Benefits from genetic resources could<br />

play an important role in improving their livelihoods<br />

as well as stimulating better use of stocks of genetic<br />

materials. The resulting gains could thus be spread<br />

more widely between developing and developed<br />

countries.<br />

A key CBD objective is the fair and equitable sharing<br />

of benefits arising from the utilisation of genetic re-<br />

Sector<br />

Pharmaceutical<br />

Biotechnology<br />

Crop protection products<br />

Agricultural seeds<br />

Ornamental horticulture<br />

Personal care, botanical<br />

and food & beverage<br />

industries<br />

sources. Following the call for action by Heads of<br />

State at the World Summit for Sustainable Development<br />

(Johannesburg, 2002), negotiations are now<br />

under way within the CBD to develop a dedicated international<br />

regime to implement relevant provisions of<br />

the Convention (see 5.3.3 and 5.3.4 below).<br />

5.3.1 THE VALUE OF GENETIC<br />

RESOURCES<br />

Genetic resources provide source material for a range<br />

of commercial products from mainstream pharmaceutical<br />

to botanical medicines, new seed varieties, ornamental<br />

horticultural products, new enzymes and<br />

microorganisms for biotechnology, crop protection products<br />

and personal care and cosmetic products. Table<br />

5.2 presents data on the estimated size of the market<br />

for these product categories and the percentage derived<br />

from genetic inputs to provide an indication of<br />

the economic value of activities dependent on genetic<br />

resources.<br />

A key question in the ABS context is how much of the<br />

Table 5.2: Market sectors dependent on genetic resources<br />

Size of Market<br />

US$ 640 bn. in 2006<br />

US$ 70 bn. in 2006 from public<br />

companies alone<br />

US$ 30 bn. in 2006<br />

US$ 30 bn. in 2006<br />

Global import value US$ 14 bn<br />

in 2006<br />

US$ 22 bn. for herbal supplements<br />

US$ 12 bn. for personal care<br />

US$ 31 bn for food products<br />

All in 2006<br />

Comment<br />

25-50% derived from genetic resources<br />

Many products derived from genetic resources<br />

(enzymes, microorganisms)<br />

Some derived from genetic resources<br />

All derived from genetic resources<br />

All derived from genetic resources<br />

Some products derived from genetic<br />

resources. Represents ‘natural’ component<br />

of the market.<br />

<strong>TEEB</strong> FOR NATIONAL AND INTERNATIONAL POLICY MAKERS - CHAPTER 5: PAGE 34<br />

Source: SCBD 2008

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!